Trial Profile
An Open Label, Dose Escalation Study to Assess Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) in Subjects With Uterine Leiomyoma (Fibroids)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs Collagenase clostridium histolyticum (Primary)
- Indications Uterine leiomyoma
- Focus Adverse reactions
- Sponsors BioSpecifics Technologies Corporation
- 09 Aug 2019 According to a BioSpecifics Technologies Corp. media release, the company is analyzing data from this trial to guide the design of a Phase 2 study of collagenase clostridium histolyticum (CCH) for the treatment of uterine fibroids. The company will present new data from the trial at an upcoming medical meeting in the second half of 2019.
- 10 May 2019 Status changed from active, no longer recruiting to completed, according to the BioSpecifics Technologies Corp. media release.
- 02 Apr 2019 According to BioSpecifics Technologies Corp. media release, results were presented at the 66th Annual Meeting of the Society for Reproductive Investigation.